BCG
RXRX icon

Breakwater Capital Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Breakwater Capital Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-10,089
Closed -$37K – 404
2026
Q2 		$37K Sell
10,089
-7,383
-42% -$24.6K ﹤0.01% 376
2026
Q1 		$53.6K Sell
17,472
-2,225
-11% -$8.6K 0.01% 373
2025
Q4 		$80.6K Buy
+19,697
New +$97.6K 0.01% 352

Other funds holding RXRX

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
TWM
TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Breakwater Capital Group's RXRX Position: Q3 2026 in Review

Breakwater Capital Group sold out of Recursion Pharmaceuticals (RXRX) in Q3 2026, closing a stake of 10,089 shares — an estimated $37K sold.

Breakwater Capital Group first reported a position in RXRX in Q4 2025 and held it in 3 quarters. The position peaked at $80.6K in Q4 2025. 21 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Breakwater Capital Group reported no remaining Recursion Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Breakwater Capital Group sold 10,089 Recursion Pharmaceuticals shares in Q3 2026, an estimated $37K.
  • Breakwater Capital Group first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Breakwater Capital Group's Recursion Pharmaceuticals position peaked at $80.6K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Breakwater Capital Group's 13F filing for Q3 2026, filed 9 Oct 2026.